Asian Spectator


The Times

.

Guangdong Goods Go Global Promotional Video Released, Extending an Invitation to the World from Guangdong

SHENZHEN, CHINA – Media OutReach Newswire – 18 November 2026 – On November 18–19, the 33rd APEC Economic Leaders' Meeting kicks off in Shenzhen, drawing global attention to Gu...

Chunghwa Telecom and PChome Form Strategic Partnership to Establish “CHT-PCH NO.1” VC Platform

Two Taiwanese industry giants join forces to establish "CHT-PCH NO.1," a venture capital fund supporting Taiwan's budding startup ecosystemTAIPEI, TAIWAN - Media OutReach - March 29, 20...

Argentine President Fernandez meet with Gotion High-tech chair...

BUENOS AIRES, Argentina, June 28, 2022 /PRNewswire-AsiaNet/ -- On the afternoon of June 24, Argentine Time, Argentine President Alberto Fernandez met with Li Zhen, chairman of Gotion High-te...

Legendary US Rock Band Green Day Kick Off Asian Tour at Galaxy Arena, Making Their First Performance in China After a 15-Year Hiatus and Igniting an Unforgettable Night of Rock’n Roll

MACAU SAR - Media OutReach Newswire - 11 February 2025 -One of the world's most influential rock bands, Green Day officially launched their Asian tour on February 9 at Macau's largest indoo...

Boat and Waterfront Art Project: FY2018 Research Project for P...

TOKYO, Aug. 31, 2018 /Kyodo JBN/ -- KADOKAWA, an entertainment company whose businesses include publishing, animation and video games, will stage "Edo -->...

Angel Yeast Invests in New Enzyme Project Capable of 5,000 Ton...

YICHANG, China, Dec. 22, 2021 /PRNewswire-AsiaNet/ -- Angel Enzyme Preparation (Yichang) Co., Ltd., ("Angel Enzyme Preparation"), a wholly-owned subsidiary of Angel Yeast Co., Ltd.( https://...

Ian Chan Jeremy Lau @MIRROR Starring in EMMAS Dream Australia Campaign

HONG KONG SAR - Media OutReach - 3 August 2022 - EMMAS Australia mattress cordially invites Ian Chan and Jeremy Lau from popular boyband MIRROR to take part in the latest "Dream Australia...

The Arc in London’s Fintech District Celebrates Strong Asian Connections as It Opens Its Doors

The Arc is a new eco-friendly mixed-use development in Shoreditch, London, featuring extensive health and wellbeing credentials and amenities, 150,000 sq. ft office space and landscaped roof...

Introducing the First Multifunctional Baby Pod - Super Safe Cosy for Sleep, Change, Play and Travel

HONG KONG, CHINA - Media OutReach - 24 October 2019 - The baby box is specially designed by a renowned Singaporean designer and has been awarded a grant by the Design Sin...

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

TOKYO, Mar 26, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL).

This application is based on data from a multicenter, open-label, single-arm Phase II clinical study (study 205) conducted in Japan for patients with relapsed or refractory CTCL or PTCL to evaluate the efficacy and safety of this agent.

This study achieved the primary endpoint and exceeded a predetermined threshold with statistical significance: the objective response rate (ORR) of CTCL and PTCL patients in total (n=36) was 36.1% (95% confidence interval (CI): 20.8-53.8). The ORRs of each subtype were 31.6% (95% CI:12.6-56.6) for CTCL (n=19) and 41.2% (95%CI: 18.4-67.1) for PTCL (n=17).

The five most frequent adverse events observed in this study were increased aspartate aminotransferase (AST) (89.2%), increased alanine aminotransferase (ALT) (86.5%), hypoalbuminaemia (70.3%), lymphopenia (70.3%), and pyrexia (51.4%).

Denileukin diftitox (genetic recombinant) is a fusion protein of the receptor-binding portion of interleukin-2 (IL-2) and diphtheria toxin that specifically binds to the IL-2 receptor on the surface of tumoral lymphocyte. The antitumor effect of denileukin diftitox depends on the intracellular delivery of diphtheria toxin which inhibits protein synthesis and induces cell death. The agent has been evaluated as a drug with high medical need by the "Study Group for Unapproved Drugs/Off-Label Drugs for High Medical Needs"(1), and Eisai has been requested to develop it by the Ministry of Health, Labour and Welfare.

Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals.

(1) The Study Group set up within the Ministry of Health, Labour and Welfare with the purpose of contributing to enhancing the development of drugs and indications that have not been approved in Japan (unapproved drugs/off-label drugs) by pharmaceutical companies. In addition to evaluating the medical needs of unapproved drugs/off-label drugs, their responsibilities include evaluating the applicability of the drug to an Application with Public Knowledge, and the adequacy of additional clinical studies that need to be conducted for filing applications for approval, and so on.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegalzlibraryzlibraryuk casinos not on gamstophttps://www.capitolcitycinema.org/casino siteleriStreamEastStreamEastjojobetcialis 20 mg fiyat